Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-08-09 4:15 pm Purchase | 2023-08-07 | 13G | VistaGen Therapeutics, Inc. VTGN | Commodore Capital LP | 1,575,000 19.700% | 1,575,000 (New Position) | Filing History |
| 2023-04-27 4:05 pm Sale | 2023-04-24 | 13G | Ambrx Biopharma Inc. AMAM | Commodore Capital LP | 31,181,983 8.100% | -4,518,017 (-12.66%) | Filing History |
| 2023-04-24 4:05 pm Purchase | 2023-04-14 | 13G | Enliven Therapeutics, Inc. ELVN | Commodore Capital LP | 2,082,123 5.100% | 633,483 (+43.73%) | Filing History |
| 2023-04-20 4:05 pm Purchase | 2023-04-10 | 13G | Adverum Biotechnologies, Inc. ADVM | Commodore Capital LP | 615,814 6.100% | 615,814 (New Position) | Filing History |
| 2023-03-30 4:05 pm Purchase | 2023-03-20 | 13G | BELLUS Health Inc. BLU | Commodore Capital LP | 6,579,359 5.200% | 1,275,802 (+24.06%) | Filing History |
| 2023-03-03 4:10 pm Purchase | 2023-02-23 | 13G | Ambrx Biopharma Inc. AMAM | Commodore Capital LP | 35,700,000 13.200% | 9,450,000 (+36.00%) | Filing History |
| 2023-03-03 4:05 pm Purchase | 2023-02-21 | 13G | Ambrx Biopharma Inc. AMAM | Commodore Capital LP | 26,250,000 9.700% | 26,250,000 (New Position) | Filing History |
| 2023-02-28 4:05 pm Purchase | 2023-02-23 | 13G | Enliven Therapeutics, Inc. ELVN | Commodore Capital LP | 1,448,640 3.500% | 1,448,640 (New Position) | Filing History |
| 2023-02-21 4:05 pm Purchase | 2023-02-15 | 13G | Bitwise MARA Option Income Strategy ETF IMRA | Commodore Capital LP | 710,189 10.800% | 86,490 (+13.87%) | Filing History |
| 2023-02-16 4:05 pm Purchase | 2023-02-06 | 13G | Vera Bradley, Inc. VRA | Commodore Capital LP | 2,342,857 5.600% | 2,342,857 (New Position) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Bitwise MARA Option Income Strategy ETF IMRA | Commodore Capital LP | 623,699 9.500% | 249,221 (+66.55%) | Filing History |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | Commodore Capital LP | 129,041 1.700% | -138,363 (-51.74%) | Filing History |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | Commodore Capital LP | 0 0.000% | -348,530 (Position Closed) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 2,020,166 5.000% | 2,020,166 (New Position) | Filing History |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | BELLUS Health Inc. BLU | Commodore Capital LP | 5,303,557 4.200% | -153,553 (-2.81%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY | Commodore Capital LP | 5,738,500 6.800% | 318,604 (+5.88%) | Filing History |
| 2023-02-14 4:06 pm Sale | 2022-12-31 | 13G | Immunic, Inc. IMUX | Commodore Capital LP | 2,873,563 6.300% | -893,013 (-23.71%) | Filing History |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | Celcuity Inc. CELC | Commodore Capital LP | 2,257,412 9.900% | 1,336,948 (+145.25%) | Filing History |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 2,732,567 5.900% | 2,732,567 (New Position) | Filing History |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | Cogent Biosciences, Inc. COGT | Commodore Capital LP | 4,926,000 7.000% | 2,644,685 (+115.93%) | Filing History |